Yesterday, July 6, 2016, 44 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $29.28 to $15,030,134.21.

Highlighted Stocks Traded by Insiders:

Egalet (EGLT) - FREE Research Report

Radie Robert S, who is President and CEO at Egalet, sold 15,000 shares at $5.01 on July 6, 2016. Following this transaction, the President and CEO owned 249,900 shares meaning that the stake was reduced by 5.66% with the 15,000-share transaction.

Musial Stan, who is Chief Financial Officer at Egalet, sold 13,480 shares at $5.06 on July 6, 2016. Following this transaction, the Chief Financial Officer owned 81,460 shares meaning that the stake was reduced by 14.2% with the 13,480-share transaction.

The shares most recently traded at $5.13, up $0.07, or 1.42% since the insider transaction. Historical insider transactions for Egalet go as follows:

  • 4-Week # shares sold: 9,236
  • 12-Week # shares sold: 9,236
  • 24-Week # shares sold: 37,812

The average volume for Egalet has been 132,000 shares per day over the past 30 days. Egalet has a market cap of $127.9 million and is part of the health care sector and drugs industry. Shares are down 54.08% year-to-date as of the close of trading on Wednesday.

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. Currently, there are 2 analysts who rate Egalet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGLT - FREE

TheStreet Quant Ratings

rates Egalet as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Egalet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Foundation Medicine (FMI) - FREE Research Report

Daly David, who is Chief Commercial Officer at Foundation Medicine, sold 5,008 shares at $17.76 on July 6, 2016. Following this transaction, the Chief Commercial Officer owned 109,450 shares meaning that the stake was reduced by 4.38% with the 5,008-share transaction.

Pellini Michael J, who is Chief Executive Officer at Foundation Medicine, sold 10,160 shares at $17.63 on July 6, 2016. Following this transaction, the Chief Executive Officer owned 339,899 shares meaning that the stake was reduced by 2.9% with the 10,160-share transaction.

Miller Vincent A., who is Chief Medical Officer at Foundation Medicine, sold 4,828 shares at $17.60 on July 6, 2016. Following this transaction, the Chief Medical Officer owned 113,654 shares meaning that the stake was reduced by 4.07% with the 4,828-share transaction.

Kafka Steven J., who is President & COO at Foundation Medicine, sold 6,495 shares at $17.67 on July 6, 2016. Following this transaction, the President & COO owned 109,731 shares meaning that the stake was reduced by 5.59% with the 6,495-share transaction.

Ryan Jason, who is Chief Financial Officer at Foundation Medicine, sold 4,687 shares at $17.63 on July 6, 2016. Following this transaction, the Chief Financial Officer owned 70,011 shares meaning that the stake was reduced by 6.27% with the 4,687-share transaction.

Hesslein Robert W., who is SVP and General Counsel at Foundation Medicine, sold 4,705 shares at $17.62 on July 6, 2016. Following this transaction, the SVP and General Counsel owned 107,061 shares meaning that the stake was reduced by 4.21% with the 4,705-share transaction.

The shares most recently traded at $21.30, up $3.68, or 17.25% since the insider transaction. Historical insider transactions for Foundation Medicine go as follows:

  • 4-Week # shares bought: 9,100
  • 4-Week # shares sold: 472
  • 12-Week # shares bought: 9,100
  • 12-Week # shares sold: 472
  • 24-Week # shares bought: 9,100
  • 24-Week # shares sold: 1,653

The average volume for Foundation Medicine has been 207,900 shares per day over the past 30 days. Foundation Medicine has a market cap of $658.5 million and is part of the health care sector and health services industry. Shares are up 0.1% year-to-date as of the close of trading on Wednesday.

Foundation Medicine, Inc. provides various molecular information products in the United States. Currently, there is 1 analyst who rates Foundation Medicine a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMI - FREE

TheStreet Quant Ratings

rates Foundation Medicine as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, deteriorating net income and feeble growth in its earnings per share. Get the full

Foundation Medicine Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

InterCloud Systems (ICLD) - FREE Research Report

Munro Mark E/Nj, who is Chairman and CEO at InterCloud Systems, bought 72,463 shares at $0.69 on July 6, 2016. Following this transaction, the Chairman and CEO owned 1.6 million shares meaning that the stake was boosted by 4.67% with the 72,463-share transaction.

Durfee Mark, who is Director at InterCloud Systems, bought 72,463 shares at $0.69 on July 6, 2016. Following this transaction, the Director owned 632,428 shares meaning that the stake was boosted by 12.94% with the 72,463-share transaction.

The shares most recently traded at $0.66, down $0.03, or 4.55% since the insider transaction. Historical insider transactions for InterCloud Systems go as follows:

  • 4-Week # shares bought: 125,000
  • 12-Week # shares bought: 125,000
  • 24-Week # shares bought: 125,000

The average volume for InterCloud Systems has been 240,300 shares per day over the past 30 days. InterCloud Systems has a market cap of $22.5 million and is part of the technology sector and computer software & services industry. Shares are down 35.2% year-to-date as of the close of trading on Wednesday.

InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally. The company has a P/E ratio of 0.2. Currently, there are no analysts who rate InterCloud Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICLD - FREE

TheStreet Quant Ratings

rates InterCloud Systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

InterCloud Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.